WHO ICTRP trial
A randomised Phase II study of two chemotherapy regimens…
EUCTR2006-000441-19-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-000441-19-DE |
|---|---|
| Public title | A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients. |
| Scientific title | A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients. |
| Primary sponsor | Eli lilly and Company Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Spain;Germany;Italy |
| Conditions | advanced breast cancer MedDRA version: 8.0 Level: LLT Classification code 10006285 |
| Interventions | Trade Name: Alimta 500 mg Product Name: Alimta 500mg Product Code: LY231514 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Pemetrexed CAS Number: 150399-23-8 Current Sponsor code: LY231514 disodium Concentration… |
| Registration date | Feb 24, 2006 |
| Target size | 144 |
| Secondary IDs | H3E-EW-S098 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: